KORE Receives Notice from NYSE Regarding Continued Listing Standards

KORE Group Holdings Faces NYSE Compliance Issue September 16, 2024 ATLANTA KORE Group Holdings, Inc. (NYSE: KORE) recently announced that it is not in compliance with Section 802.01B of the NYSE’s Listed Company Manual. This non-compliance stems from KORE’s average global market capitalization and stockholders’ equity falling below $50 million over a consecutive 30 trading-day…

Read More

Unconventional and Charming: A Refreshing Take on Accesswire’s Latest Article (ID: 918208)

Clever, Personable, and Unconventional: A Look at Safety Strips, Inc.’s Drink Spike Test Strips Safety Strips, Inc. has made waves in the market with its low-cost test strip that provides an affordable, reliable way for people to test substances for two dangerous adulterants that are contributing to the growing opioid epidemic. The Drink Spike Test…

Read More

Unlocking the Power of HTML Markup: A Guide to Creating Engaging and Professional Content

Cosmos Health Inc. Extends Distribution Agreement with Virax Biolabs Chicago, IL / Accesswire / September 16, 2024 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, has announced an extension of its exclusive distribution agreement with Virax Biolabs (NASDAQ: VRAX). This agreement allows Cosmos Health to commercialize…

Read More

Say Hello to Autocado: Chipotle’s Latest Innovation in Restaurant Tech!

Cultivating the Future: Chipotle’s Cobots Revolutionizing the Restaurant Industry Embracing the Robot Revolution Picture this: you walk into your favorite Chipotle location, ready to indulge in a delicious burrito bowl. As you make your way to the front of the line, you notice something different. There, alongside the Chipotle crew members, are sleek, futuristic robots…

Read More

Unlocking the Potential: NextCure Shares Promising Findings from NC410 and Pembrolizumab Combination Study at ESMO 2024

NextCure Presents Clinical Data on NC410 at ESMO 2024 Introduction NextCure, Inc. (Nasdaq: NXTC), a leading biopharmaceutical company, recently announced exciting clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab. This groundbreaking research was presented at ESMO 2024, showcasing promising results in…

Read More